Radioimmunotherapy with (90)Y-ibritumomab tiuxetan is a safe and efficient treatment for patients with B-cell lymphoma relapsed after auto-SCT: an analysis of the international RIT-Network.
Hohloch
K
K
Zinzani
P L
PL
Linkesch
W
W
Jurczak
W
W
Deptala
A
A
Lorsbach
M
M
Windemuth-Kiesselbach
C
C
Wulf
G G
GG
Truemper
L H
LH
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003625:Data Collection; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016393:Lymphoma, B-Cell / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D016499:Radioimmunotherapy / Q000379:methods; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D055815:Young Adult; D015021:Yttrium Radioisotopes / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D015021:Yttrium Radioisotopes; C422802:ibritumomab tiuxetan